Related Experiment Video
Updated: May 15, 2026
08:38
Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
Published on: September 1, 2011
[Vinpocetin in neurological diseases]
László Szapáry1, Gábor Késmárky, Kálmán Tóth
1Pécsi Tudományegyetem, OEKK KK, Neurológiai KIínika, Pécs.
Ideggyogyaszati Szemle
|January 8, 2013
Summary
Vinpocetine demonstrates neuroprotective effects and improves cerebral blood flow in neurological conditions. While its efficacy in acute stroke remains unclear, it shows promise for chronic cerebrovascular diseases and cognitive function enhancement.
Area of Science:
- Pharmacology
- Neuroscience
- Cerebrovascular Medicine
Context:
- Stroke is a leading cause of death and disability globally.
- Cerebral hypoperfusion is implicated in various neurological disorders.
- No current salvage therapy exists for irreversibly damaged brain areas post-stroke.
Purpose:
- To review experimental and clinical literature on vinpocetine's role in neurological conditions.
- To evaluate vinpocetine's therapeutic potential in cerebrovascular diseases.
Summary:
- Vinpocetine exhibits anti-inflammatory, antioxidant, vasodilating, antiepileptic, and neuroprotective properties in experimental models.
- Meta-analyses have not confirmed vinpocetine's efficacy in acute stroke fatality rates.
- In chronic cerebrovascular patients, vinpocetine improves hemorheology, endothelial function, and cerebral blood flow, potentially enhancing cognitive functions.
Impact:
- Vinpocetine is a significant agent in both basic research and clinical management of neurological diseases.
- Further research may elucidate its role in preventing or treating neurological conditions linked to hypoperfusion.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:29Drug Delivery: Parenteral Route
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Increased Intracranial Pressure ll: Pathophysiology
Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins with...